Avadel Pharmaceuticals announced that it is commencing an underwritten public offering of its ordinary shares, in the form of American Depositary Shares. Each ADS represents the right to receive one Ordinary Share. Jefferies is acting as the sole book-running manager for the offering. LifeSci Capital is acting as lead manager for the offering. H.C. Wainwright & Co., Oppenheimer & Co., and Needham & Company are acting as co-managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AVDL:
- Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30
- Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares
- Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering of ADSs and Series B Preferred Shares
- Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million